Upgrade to SI Premium - Free Trial

BMO Capital Shares Thoughts on Novo Nordisk (NVO) Following The Hims Agreement

March 10, 2026 8:50 AM
BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $45.00 price target on Novo Nordisk (NYSE: NVO).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments